Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data

DOI Web Site 4 Citations 21 References

Shun Kohsaka

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan;
Tatsunori Murata

Crecon Medical Assessment Inc., Tokyo, Japan;
Naoko Izumi

Pfizer Japan Inc., Tokyo, Japan;
Jun Katada

Pfizer Japan Inc., Tokyo, Japan;
Feng Wang

Bristol-Myers Squibb Co., NY, USA;
Yasuo Terayama

Department of Gerontology, School of Medicine, Iwate Medical University, Iwate, Japan

Journal

Current Medical Research and Opinion

Current Medical Research and Opinion 33 (11), 1955-1963, 2017-09-12

Informa UK Limited

Back to top